PSME3: A Potential Drug Target and Biomarker for Activator of Multicatalytic Protease Subunit 3

Target Name: PSME3

NCBI ID: G10197

PSME3

PSME3: A Potential Drug Target and Biomarker for Activator of Multicatalytic Protease Subunit 3

Protease is an essential enzyme that contributes to various cellular processes, including DNA replication, virus infection, and cellular signaling. The activity of proteases can be inhibited by various drugs, including small molecules and biochemicals. One of the proteases that has received significant attention in recent years is activator of multicatalytic protease subunit 3 (PSME3). This enzyme has been shown to play a critical role in cell signaling and has potential as a drug target or biomarker. In this article, we will provide an overview of PSME3, its function, and potential as a drug target or biomarker.

PSME3: Structure and Function

PSME3 is a member of the serine protease family 6, which includes other well-known enzymes such as thrombin, trypsin, and chymotrypsin. These enzymes belong to the group of maturation-promoting enzymes (MPEs), which are characterized by the presence of a specific active site and a unique substrate specificity. PSME3 has a molecular weight of 126 kDa and a pre-protein cleavage activity of 128 kDa.

PSME3 plays a critical role in cellular signaling by regulating various cellular processes, including cell signaling, cell death, and cell division. One of the well-known functions of PSME3 is its role in cell signaling via the production of pro-inflammatory cytokines, such as TNF-?±, IL-1??, and IL-6. These cytokines play a crucial role in cellular signaling and are involved in the regulation of various cellular processes, including immune response, inflammation, and tissue repair.

PSME3 has also been shown to play a critical role in the regulation of cell cycle progression. It has been shown to be involved in the G1/S transition, G2/M transition, and G0/G1 transition. These transitions are critical periods in the cell cycle and are involved in the regulation of various cellular processes, including cell growth, apoptosis, and DNA replication.

PSME3 has also been shown to play a critical role in the regulation of cellular signaling by controlling the activity of various enzymes, including cyclin D1, p21, and p53. These enzymes are involved in the regulation of cell cycle progression and have been shown to be regulated by PSME3.

PSME3 as a Drug Target

PSME3 has received significant attention as a drug target due to its various functions and its involvement in cellular signaling. Several small molecules and biochemicals have been shown to inhibit the activity of PSME3 and enhance its sensitivity to inhibition. These compounds have been shown to act as either positive or negative regulators of PSME3, depending on their specific structure and function.

One of the well-known small molecules that has been shown to inhibit the activity of PSME3 is the inhibitor IDN-1023. IDN-1023 is a peptide that contains a unique amino acid sequence that is similar to the active site of PSME3. The presence of this sequence allows IDN-1023 to bind to the active site of PSME3 and inhibit its activity.

Another small molecule that has been shown to inhibit the activity of PSME3 is the inhibitor U-8553. U-8553 is a peptide that contains a unique amino acid sequence that is similar to the active site of PSME3. The presence of this sequence allows U-8553 to bind to the active site of PSME3 and inhibit its activity.

One of the potential benefits of these inhibitors is that they can be used to treat various diseases that are caused by the activity of PSME3. For example, the activity of PSME3 has

Protein Name: Proteasome Activator Subunit 3

Functions: Subunit of the 11S REG-gamma (also called PA28-gamma) proteasome regulator, a doughnut-shaped homoheptamer which associates with the proteasome. 11S REG-gamma activates the trypsin-like catalytic subunit of the proteasome but inhibits the chymotrypsin-like and postglutamyl-preferring (PGPH) subunits. Facilitates the MDM2-p53/TP53 interaction which promotes ubiquitination- and MDM2-dependent proteasomal degradation of p53/TP53, limiting its accumulation and resulting in inhibited apoptosis after DNA damage. May also be involved in cell cycle regulation. Mediates CCAR2 and CHEK2-dependent SIRT1 inhibition (PubMed:25361978)

The "PSME3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSME3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets